Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 8/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974907 | 0.83 | PTPN5 (0.58) | HTR7ARPDK2PTPN5RORC | |
| SCHEMBL321574 | 0.76 | AR (0.50) | HTR7ARPDK2PTPN5RORC | |
| SCHEMBL17974909 | 0.76 | NR1H2 (0.44) | PTPN1 | |
| SCHEMBL17974974 | 0.75 | TSHR (0.52) | — | |
| SCHEMBL17974910 | 0.75 | MKNK1 (0.44) | PDK2 | |
| SCHEMBL10094733 | 0.75 | HTR7 (0.46) | HTR7ARPDK2PTPN5HTR1A | |
| SCHEMBL17974916 | 0.73 | MAOB (0.41) | ARPDK2 | |
| SCHEMBL20724250 | 0.73 | PTPN5 (0.37) | HTR7PTPN5MCL1 | |
| SCHEMBL17974819 | 0.73 | AKT1 (0.40) | PDK2 | |
| SCHEMBL20724251 | 0.72 | PTPN5 (0.43) | HTR7ARPDK2PTPN5RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | HTR7 4395/4885AR 4088/4885PDK2 3140/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | HTR7 4395/4885AR 4088/4885PDK2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.